Blood clot prevention medicine for teens in intensive care
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a daily injection of a blood-thinning medicine called enoxaparin (Lovenox) can safely prevent dangerous blood clots in teens who are critically ill in the intensive care unit with an IV line and an infection or inflammation. It may help reduce the risk of blood clots without causing excess bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 12 and 18 years old.
- Be admitted to the pediatric intensive care unit (PICU) within the last 24 hours.
- Have a central venous catheter (a special IV line) in place.
- Have a suspected or confirmed infection or severe inflammation.
- No major surgery or serious injury in the last week.
- Not be currently taking blood-thinning medications other than for IV line maintenance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a short course of a daily blood-thinning injection (enoxaparin) after childbirth can safely prevent blood clots in women at intermediate risk. If you qualify, you would receive the injection or a placebo (inactive shot) for up to 5 days while in the hospital.
This study tests two experimental drugs, REGN7508 and REGN9933, to see if they can safely prevent blood clots in the arm or chest in people who need a PICC line. If you are getting a PICC for treatments like chemotherapy or antibiotics, you may be able to join.
This trial tests whether starting enoxaparin (a blood-thinner) within 24 hours after placing a specific type of central line can prevent dangerous clots. It may help reduce clot risk in people whose line is placed in the neck or thigh vein, while also tracking bleeding side effects.
This trial tests whether giving a blood thinner before placing a central line (a special IV) helps prevent clots in critically ill children. It could lower the risk of problems from the line.
This study looks at a prevention plan to reduce the risk of hospital-acquired blood clots. It may help people who are expected to stay in the hospital for several days but do not already have a clot.
This study compares two doses of a blood thinner (enoxaparin) to see which better prevents blood clots in patients with severe injuries who are in the intensive care unit. It helps doctors choose the best dose to keep you safe and healthy.
Hear when a new Venous Thromboembolism (VTE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.